Neuroendocrine Tumors

Oncology
18
Pipeline Programs
11
Companies
25
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
3
9
1
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
862%
Peptide
431%
Monoclonal Antibody
18%
+ 13 programs with unclassified modality

Competitive Landscape

11 companies ranked by most advanced pipeline stage

H
HutchmedChina - Hong Kong
5 programs
1
1
2
SurufatinibPhase 3Small Molecule1 trial
SurufatinibPhase 3Small Molecule1 trial
SurufatinibPhase 1/2Small Molecule1 trial
SulfatinibPhase 1Small Molecule1 trial
SurufatinibN/ASmall Molecule1 trial
Active Trials
NCT04814732No Longer Available
NCT02267967Completed81Est. Aug 2017
NCT05077384Completed36Est. Jan 2025
+2 more trials
RadioMedix
RadioMedixTX - Houston
2 programs
1
1
64Cu-DOTATATEPhase 31 trial
Indium-111 pentetreotidePhase 2/3Peptide1 trial
Active Trials
NCT00442533CompletedEst. Dec 2015
NCT03673943CompletedEst. Aug 2019
Ipsen
IpsenChina - Tianjin
7 programs
1
1
LanreotidePhase 2Peptide1 trial
Satoreotide tetraxetanPhase 1/2Peptide1 trial
Data collectionN/A1 trial
Data collectionN/A1 trial
Data collectionN/A1 trial
+2 more programs
Active Trials
NCT03112694Completed93Est. Nov 2017
NCT03562091Completed115Est. May 2020
NCT03220087Completed142Est. Apr 2018
+4 more trials
Novartis
NovartisBASEL, Switzerland
4 programs
1
1
Lutetium Lu 177 dotatate therapyPhase 21 trial
68Ga-DOTA-MGS5Phase 1/21 trial
Neuroendocrine Tumors of Old Patients in the West of FranceN/A1 trial
The Patient's Journey - the Time to Final Diagnosis in Patients With SiNETN/A1 trial
Active Trials
NCT03749681Unknown306Est. Mar 2020
NCT03840720Completed20Est. Dec 2019
NCT06155994Completed12Est. Jun 2023
+1 more trials
Genentech
GenentechCA - Oceanside
2 programs
2
BevacizumabPhase 2Monoclonal Antibody1 trial
RAD001Phase 2
Active Trials
NCT00137774Completed34Est. Dec 2012
Sanofi
SanofiPARIS, France
1 program
1
AlphaMedixPhase 21 trial
Active Trials
NCT05153772Active Not Recruiting69Est. Oct 2028
E
EisaiChina - Liaoning
1 program
1
LenvatinibPhase 2Small Molecule1 trial
Active Trials
NCT02678780Completed123Est. Aug 2020
M&
Merck & Co.RAHWAY, NJ
1 program
1
MK-0646Phase 21 trial
Active Trials
NCT00610129Completed25Est. Jan 2010
Recordati
RecordatiFrance - Saint-Victor
1 program
1
Pasireotide Long Acting ReleasePhase 2Peptide1 trial
Active Trials
NCT01253161Completed29Est. Mar 2023
TerSera Therapeutics
TerSera TherapeuticsIL - Deerfield
1 program
1
TelotristatPhase 2Small Molecule1 trial
Active Trials
NCT04543955TerminatedEst. Jun 2022
Providence Therapeutics
1 program
1
CabozantinibPhase 1Small Molecule1 trial
Active Trials
NCT05249114Active Not Recruiting6Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
RadioMedix64Cu-DOTATATE
HutchmedSurufatinib
HutchmedSurufatinib
RadioMedixIndium-111 pentetreotide
NovartisLutetium Lu 177 dotatate therapy
SanofiAlphaMedix
TerSera TherapeuticsTelotristat
IpsenLanreotide
EisaiLenvatinib
RecordatiPasireotide Long Acting Release
Merck & Co.MK-0646
GenentechBevacizumab
HutchmedSurufatinib
Novartis68Ga-DOTA-MGS5
IpsenSatoreotide tetraxetan

Showing 15 of 24 trials with date data

Clinical Trials (25)

Total enrollment: 1,879 patients across 25 trials

NCT03673943RadioMedix64Cu-DOTATATE

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

Start: Aug 2018Est. completion: Aug 2019
Phase 3Completed
NCT02588170HutchmedSurufatinib

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Start: Dec 2015Est. completion: Jul 2022219 patients
Phase 3Completed
NCT02589821HutchmedSurufatinib

Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

Start: Dec 2015Est. completion: Jul 2022195 patients
Phase 3Completed
NCT00442533RadioMedixIndium-111 pentetreotide

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Start: Aug 2005Est. completion: Dec 2015
Phase 2/3Completed
NCT06395402NovartisLutetium Lu 177 dotatate therapy

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

Start: May 2024Est. completion: Dec 2029120 patients
Phase 2Recruiting
NCT05153772SanofiAlphaMedix

Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients

Start: Dec 2021Est. completion: Oct 202869 patients
Phase 2Active Not Recruiting
NCT04543955TerSera TherapeuticsTelotristat

Telotristat With Lutathera in Neuroendocrine Tumors

Start: Sep 2021Est. completion: Jun 2022
Phase 2Terminated
NCT02859064IpsenLanreotide

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Start: Jul 2017Est. completion: Jun 20226 patients
Phase 2Terminated
NCT02678780EisaiLenvatinib

Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors

Start: Oct 2015Est. completion: Aug 2020123 patients
Phase 2Completed
NCT01253161RecordatiPasireotide Long Acting Release

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Start: Feb 2011Est. completion: Mar 202329 patients
Phase 2Completed
NCT00610129Merck & Co.MK-0646

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

Start: Jan 2008Est. completion: Jan 201025 patients
Phase 2Completed
NCT00137774GenentechBevacizumab

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Start: Nov 2004Est. completion: Dec 201234 patients
Phase 2Completed
NCT05077384HutchmedSurufatinib

Open-label Study of Surufatinib in Japanese Patients

Start: Sep 2021Est. completion: Jan 202536 patients
Phase 1/2Completed
NCT06155994Novartis68Ga-DOTA-MGS5

68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours

Start: Jan 2021Est. completion: Jun 202312 patients
Phase 1/2Completed
NCT02592707IpsenSatoreotide tetraxetan

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Start: Mar 2017Est. completion: Feb 202240 patients
Phase 1/2Terminated
NCT05249114Providence TherapeuticsCabozantinib

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Start: Dec 2022Est. completion: Dec 20266 patients
Phase 1Active Not Recruiting
NCT02267967HutchmedSulfatinib

Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

Start: Oct 2014Est. completion: Aug 201781 patients
Phase 1Completed
NCT04814732HutchmedSurufatinib

Expanded Access Program of Surufatinib

N/ANo Longer Available
NCT04365023Ipsenplatinum chemotherapy

Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors

Start: Jul 2020Est. completion: May 2023168 patients
N/ACompleted
NCT03840720NovartisThe Patient's Journey - the Time to Final Diagnosis in Patients With SiNET

The Patient's Journey - the Time to Final Diagnosis in Patients With SiNET

Start: Feb 2019Est. completion: Dec 201920 patients
N/ACompleted
NCT03749681NovartisNeuroendocrine Tumors of Old Patients in the West of France

Neuroendocrine Tumors of Old Patients in the West of France

Start: Dec 2018Est. completion: Mar 2020306 patients
N/AUnknown
NCT03562091IpsenData collection

Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel

Start: Jul 2018Est. completion: May 2020115 patients
N/ACompleted
NCT03220087IpsenData collection

Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain

Start: Jul 2017Est. completion: Apr 2018142 patients
N/ACompleted
NCT03112694IpsenData collection

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Start: Apr 2017Est. completion: Nov 201793 patients
N/ACompleted
NCT00747786IpsenNon Interventional Post Marketing Programme in Neuroendocrine Tumours

Non Interventional Post Marketing Programme in Neuroendocrine Tumours

Start: Dec 2008Est. completion: Aug 201340 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,879 patients
11 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)